IRIS
CASSANITI, IRENE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.525
AS - Asia 2.486
EU - Europa 1.727
SA - Sud America 398
Continente sconosciuto - Info sul continente non disponibili 143
AF - Africa 140
OC - Oceania 6
Totale 8.425
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.378
SG - Singapore 723
CN - Cina 687
HK - Hong Kong 362
IT - Italia 352
RU - Federazione Russa 337
VN - Vietnam 312
BR - Brasile 302
DE - Germania 231
IE - Irlanda 225
FR - Francia 135
FI - Finlandia 132
GB - Regno Unito 103
ZA - Sudafrica 85
IN - India 79
CA - Canada 66
BD - Bangladesh 62
MX - Messico 48
JP - Giappone 47
PL - Polonia 38
AR - Argentina 30
ES - Italia 29
NL - Olanda 29
IQ - Iraq 28
TR - Turchia 28
PK - Pakistan 25
SE - Svezia 24
ID - Indonesia 20
VE - Venezuela 19
AT - Austria 17
PH - Filippine 17
CL - Cile 13
MA - Marocco 11
BE - Belgio 10
CZ - Repubblica Ceca 10
CH - Svizzera 9
EC - Ecuador 9
LT - Lituania 9
SA - Arabia Saudita 9
TN - Tunisia 9
UA - Ucraina 9
UZ - Uzbekistan 9
CO - Colombia 8
MY - Malesia 8
EG - Egitto 7
KE - Kenya 7
TH - Thailandia 7
IL - Israele 6
PY - Paraguay 6
AU - Australia 5
AZ - Azerbaigian 5
CR - Costa Rica 5
IR - Iran 5
JM - Giamaica 5
KZ - Kazakistan 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
ET - Etiopia 4
HR - Croazia 4
JO - Giordania 4
KR - Corea 4
LK - Sri Lanka 4
NI - Nicaragua 4
NP - Nepal 4
PE - Perù 4
DK - Danimarca 3
GR - Grecia 3
HN - Honduras 3
KG - Kirghizistan 3
LV - Lettonia 3
MU - Mauritius 3
PA - Panama 3
RO - Romania 3
SN - Senegal 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AM - Armenia 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
LB - Libano 2
PR - Porto Rico 2
PS - Palestinian Territory 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TZ - Tanzania 2
AS - Samoa Americane 1
BA - Bosnia-Erzegovina 1
BZ - Belize 1
CG - Congo 1
CI - Costa d'Avorio 1
CM - Camerun 1
CU - Cuba 1
DM - Dominica 1
EE - Estonia 1
GT - Guatemala 1
GY - Guiana 1
Totale 8.265
Salva come PNG Salva come JPEG
Città #
San Jose 556
Dallas 410
Singapore 408
Ashburn 373
Hong Kong 353
Beijing 214
Dublin 207
Council Bluffs 201
Chandler 175
New York 157
Munich 131
Los Angeles 109
Ho Chi Minh City 106
Boardman 103
Lauterbourg 92
Helsinki 83
Hanoi 75
Johannesburg 75
Shanghai 73
Milan 70
Redondo Beach 63
Moscow 54
Turku 49
Santa Clara 45
Columbus 44
Seattle 41
Pavia 40
Tokyo 36
Orem 35
Princeton 32
Warsaw 32
Buffalo 30
The Dalles 28
Lawrence 27
São Paulo 27
Denver 26
Frankfurt am Main 23
Phoenix 23
Medford 22
Toronto 22
Brooklyn 20
Chicago 20
London 19
Montreal 19
Poplar 19
Wilmington 18
Atlanta 17
Mexico City 17
Rome 17
Boston 16
Chennai 16
Da Nang 16
Düsseldorf 14
San Francisco 14
Stockholm 14
Washington 14
Biên Hòa 13
Amsterdam 12
Baghdad 12
Houston 12
Ankara 11
Lahore 11
Mumbai 11
Nuremberg 11
Falkenstein 10
Charlotte 9
Haiphong 9
Tashkent 9
Belo Horizonte 8
Lecce 8
Piscataway 8
Brussels 7
Guangzhou 7
Paris 7
Querétaro 7
Santiago 7
Hyderabad 6
Hải Dương 6
Jakarta 6
Jinan 6
Manchester 6
Marseille 6
Milwaukee 6
Nairobi 6
Nanjing 6
Xi'an 6
Cairo 5
Casablanca 5
Curitiba 5
Dhaka 5
Ha Long 5
Medellín 5
Porto Alegre 5
Portsmouth 5
Pune 5
Salvador 5
San José 5
Ann Arbor 4
Bangkok 4
Bergamo 4
Totale 5.256
Salva come PNG Salva come JPEG
Nome #
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 159
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 150
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 141
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 140
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 131
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 131
Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study 130
19n01, a Broadly Neutralizing Antibody Against Omicron BA.1, BA.2, BA.4/5, and Other SARS-CoV-2 Variants of Concern 128
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 120
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020 117
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice 117
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up 116
SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers 115
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 113
Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis 112
Characterization of varicella-zoster (Vzv) specific t cell response in healthy subjects and transplanted patients by using enzyme linked immunospot (elispot) assays 108
Human Cytomegalovirus-Specific Memory CD4+T-Cell Response and Its Correlation with Virus Transmission to the Fetus in Pregnant Women with Primary Infection 107
Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects 106
Dengue Virus-Specific Humoral and T Cellular Immune Response in Italian Residents and Travelers Returning from Endemic Areas 105
Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers 103
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study 101
Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy 98
Machine Learning-based Voice Assessment for the Detection of Positive and Recovered COVID-19 Patients 97
Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, "I Am like a Box of Complexity, You Never Know What You Are Gonna Get" 95
Macrophages and monocytes: “trojan horses” in covid-19 94
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study 94
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment 93
Immunity to SARS-CoV-2 up to 15 months after infection 92
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients 92
Sars-cov-2 virologic and immunologic correlates in patients with olfactory and taste disorders 92
Authors' response: COVID-19: how accurate are seroprevalence studies? 91
Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay 90
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 89
CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection 89
Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients 88
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 88
Asymptomatic infection with clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) in carnivore pets, Italy, April 2023 87
Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2 87
Dynamics of humoral and cellular immunity elicited by the BNT162b2 mRNA vaccine in psoriatic patients under targeted immunosuppression: A longitudinal cohort study 86
Adapting Neutralizing Antibodies to Viral Variants by Structure-Guided Affinity Maturation Using Phage Display Technology 85
Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection 85
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay 85
Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017 84
Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis 83
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy 83
Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis 83
Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein 83
Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19 82
ELISPOT assays with pp65 peptides or whole HCMV antigen are reliable predictors of immune control of HCMV infection in seropositive kidney transplant recipients 82
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs 82
Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages 81
Deep learning and machine learning-based voice analysis for the detection of COVID-19: A proposal and comparison of architectures 80
Performance of new pp65-IGRA for the quantification of HCMV-specific CD4+ T-cell response in healthy subjects and in solid organ transplant recipients 79
SARS-CoV-2 positivity in rectal swabs: implication for possible transmission 79
Preliminary results on an autochthonous dengue outbreak in Lombardy Region, Italy, August 2023 78
Human Cytomegalovirus Virion‐Associated mRNA as a Marker of Productive Infection in Immunocompromised Patients 78
A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice 78
Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department 78
Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area 77
The 2023 dengue outbreak in Lombardy, Italy: A one-health perspective 75
Infectious complications and immunotherapy: old pitfalls and new horizons 75
The 'hit-and-run' strategy and viral carcinogenesis 74
Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients 74
Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease 73
Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, “I Am like a Box of Complexity, You Never Know What You Are Gonna Get” 73
Zika virus infection in pregnancy: Advanced diagnostic approaches in dengue-naive and dengue-experienced pregnant women and possible implication for cross-reactivity and cross-protection 72
Photopheresis abates the anti-hla antibody titer and renal failure progression in chronic antibody-mediated rejection 71
Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors 71
Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital 70
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern 70
Long-term dynamics of natural killer cells in response to SARS-CoV-2 vaccination: Persistently enhanced activity postvaccination 70
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice 68
Corrigendum to "Seroprevalence of SARS-CoV-2 in 1922 blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area" [Clin Microbiol Infect 27 (6) (2021 Jun) 914.e1-914.e4] 68
Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment 68
Characterization of CCP: Can We Use Past Convalescent Plasma from COVID-19 Patients for Treatment of New Emerging Variants? 67
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) 67
Immune Control of Human Cytomegalovirus (HCMV) Infection in HCMV-Seropositive Solid Organ Transplant Recipients: The Predictive Role of Different Immunological Assays 66
Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns 66
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant 65
Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection 65
High-throughput peptide array analysis and computational techniques for serological profiling of flavivirus infections: Implications for diagnostics and vaccine development 65
mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19 65
Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report 63
Molecular Epidemiology of Rhinovirus/Enterovirus and Their Role on Cause Severe and Prolonged Infection in Hospitalized Patients 61
Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit 60
Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children 60
Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit 59
SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment 57
West nile or usutu virus? A three-year follow-up of humoral and cellular response in a group of asymptomatic blood donors 57
Immune response to bnt162b2 in solid organ transplant recipients: Negative impact of mycophenolate and high responsiveness of sars-cov-2 recovered subjects against delta variant 56
Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study 51
Memory T cells specific for HBV enumerated by a peptide-based cultured enzyme-linked immunospot assay in healthy HBV-vaccinated subjects 50
Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report 48
Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM) 47
Thirteen Years of Phleboviruses Circulation in Lombardy, a Northern Italy Region 42
SARS-CoV-2 viability on different surfaces after gaseous ozone treatment: a preliminary evaluation 41
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant 39
null 37
Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection 32
Tetravalent SARS-CoV-2 S1 subunit protein vaccination elicits robust humoral and cellular immune responses in SIV-infected rhesus macaque controllers 31
Totale 8.306
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.187
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.187
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022182 0 1 5 26 12 3 4 13 4 17 16 81
2022/2023618 42 51 4 48 31 38 6 17 278 12 79 12
2023/2024664 61 113 40 31 53 161 57 45 6 22 39 36
2024/20251.919 49 95 29 104 35 125 114 77 489 127 236 439
2025/20264.682 361 291 515 514 514 196 864 280 421 322 264 140
2026/2027275 99 176 0 0 0 0 0 0 0 0 0 0
Totale 8.425